Aarti Drugs Limited — Q3 FY26
Aarti Drugs reported a mixed Q3 FY26 with consolidated revenue of ₹602.9 crore (+8% YoY) but EBITDA margin contracting to 9.3% (-180bps YoY) due to low capacity utilization, Chi...
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
High single-digit value growth in H2 FY26
Management aims for high single-digit value growth in H2 FY26, driven by export demand and new capacities.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1